Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. CSX
8. SAP
9. QGEN
10. ELV

Go back to Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements

Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results

May 10, 2016 4:05 PM EDT

DUBLIN, May 10, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2016 and updated financial guidance for 2016.

"During the first quarter of 2016, we executed on our business model by delivering strong top- and bottom-line growth and commenced promotion of Defitelio in the U.S. immediately following FDA approval. Defitelio is the first and only approved treatment in the U.S. for patients who develop hepatic VOD with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation," said Bruce C. Cozadd, chairman and chief executive... More